Brokerage Firm Rating on ABIOMED (ABMD)

ABIOMED (ABMD) has an average broker rating of 1.63, which is interpreted as a Buy, as rated by 8 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

ABIOMED (ABMD) : 6 Wall Street analysts covering ABIOMED (ABMD) believe that the average level the stock could reach for the short term is $125.17. The maximum price target given is $145 and the minimum target for short term is around $101, hence the standard deviation is calculated at $16.99.


For the current week, the company shares have a recommendation consensus of Buy. ABIOMED (NASDAQ:ABMD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $123.28 and $122.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $124.72. The buying momentum continued till the end and the stock did not give up its gains. It closed at $124.09, notching a gain of 0.51% for the day. The total traded volume was 389,947 . The stock had closed at $123.46 on the previous day.

In a related news, Thomas Paul, director of Abiomed Inc, unloaded 10,000 shares at an average price of $118.65 on August 1, 2016. The total amount of the transaction was worth $1,186,500, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Companys products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.